

Ghana Essential Medicines List



REPUBLIC OF GHANA

Ministry of Health
Ghana National Drugs Programme
(GNDP)
Fifth Edition, 2004

© 2004 Ministry of Health (GNDP) Ghana

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording and/or otherwise, without prior written permission of the Ministry of Health, Ghana

Essential Drugs List & National Formulary with Therapeutic Guidelines, 1st Edition, 1988

Essential Drugs List & National Formulary with Therapeutic Guidelines, 2nd Edition, 1993

Essential Drugs List & National Formulary with Therapeutic Guidelines, 3rd Edition, 1996

Ghana Essential Drugs List, 4th Edition, 2000

Ghana Essential Medicines List, 5th Edition, 2004

ISBN 9988-8283-2-2

For all enquiries write to the publishers:

Ghana National Drugs Programme (GNDP)
Ministry of Health
P.O. Box MB-582, Accra, Ghana, West Africa
Tel: +233 (0) 21 661 670/1
Fax: +233 (0) 21 664309
E-mail: gndp@ighmail.com
Website: www.moh-ghana.org

Printed by Yamens Press Limited, Accra, Ghana, West Africa.
Tel: +233 (0) 21 223 222

Materials Development Consultant: E.T.A. Abbey
P.O. Box AN 5116 Accra, Ghana, West Africa
Tel: + 233 (0) 21 304 211/+233 (0) 21 313 843

ACKNOWLEDGEMENTS

The review of the Essential Medicines List (EML) 2004 by the Ministry of Health has been successful largely due to the contributions from doctors, pharmacists, nurses and other health professionals from the public and the private sectors. We are grateful to the Ghana National Drugs Programme Steering Committee, the Standard Treatment Guidelines (STG) Expert Committee, the Essential Drugs List Review Committee, all Regional Directors of Health Services, all Teaching Hospitals, and all professional medical, pharmaceutical and nursing associations, Industry, Universities and individuals who contributed to the review process. It is impossible to name everyone who contributed to this edition. We thank you all for making this publication a reality. We are especially grateful to the Dutch Government and the Royal Netherlands Embassy, Accra for the generous financial assistance provided to the Ministry of Health for management support to the pharmaceutical sector in Ghana under the Ghana National Drugs Programme (GNDP) through which this activity was funded. The World Health Organisation (WHO) is also acknowledged for the financial and technical support provided for the development and publication of this edition.

The members of these various committees are:

MOH/GHS Executives:

Hon. M. Dani-Baah	Hon. Deputy Minister for Health
Dr. K. Ahmed	Chief Medical Officer, Ministry of Health (MOH)
Prof. A. B. Akosa	Director-General, Ghana Health Service
Mr. S. Boateng	Director, Procurement & Supplies, MOH
Dr. S. Akor	Director, Policy, Planning, Monitoring & Evaluation, MOH
Dr. S. Adjei	Deputy Director-General, Ghana Health Service
Dr. T. N. Awua Siaw	Institutional Care Division, Ghana Health Service
Mr. F. Yellu	Chief Pharmacist, Ghana Health Service
Mrs. J. Azeez	Drugs Manager, Procurement Unit, MOH

STG Expert Committee Members:

Dr. K. Aboah	Department of Surgery, School of Medical Sciences, Kwame Nkrumah University of Science & Technology
Prof. H. Addo	Department of Medicine, University of Ghana Medical School
Mr. P. Anum	National Drugs Information Centre, Pharmacy Council
Dr. K. Aryee	Department of Obstetrics & Gynaecology, University of Ghana Medical School
Dr. A. N. O. Dodoo	Centre for Tropical Clinical Pharmacology & Therapeutics, University of Ghana Medical School
Prof. E. H. Frimpong	Department of Medical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science & Technology
Dr. G. Klufio	Department of Surgery, University of Ghana Medical School
Prof. M. O. Mate-Kole	Department of Medicine, University of Ghana Medical School
Mr. A. Mensah	Department of Pharmacy, Komfo Anokye Teaching Hospital
Prof. S. Naaeder	Department of Surgery, University of Ghana Medical School
Mrs. F. A. Nkansah	Department of Pharmacy, Korle Bu Teaching Hospital
Dr. F. Ofei	Department of Medicine, University of Ghana Medical School

Dr. (Mrs.) E. Ofori- University Health Services, University of Ghana
Adjei

Dr. S. Ohene Department of Psychiatry, University of Ghana Medical School

Dr. I. Owusu Department of Medicine, School of Medical Sciences, Kwame Nkrumah
University of Science & Technology

Dr. (Mrs.) B. Department of Child Health, University of Ghana Medical School
Quarm-Goka

Mr. R. Tetteh Department of Pharmacy, Korle Bu Teaching Hospital

Dr. (Mrs.) J. Department of Child Health, University of Ghana Medical School
Welbeck

STG Editorial Committee Members:

Dr. A. N. O. Dodoo Centre for Tropical Clinical Pharmacology & Therapeutics, University of
Ghana Medical School

Prof. M. O. Mate- Department of Medicine, University of Ghana Medical School
Kole

Mr. A. Mensah Department of Pharmacy, Komfo Anokye Teaching Hospital

Prof.S. Naaeder Department of Surgery, University of Ghana Medical School

Mrs. F. A. Nkansah Department of Pharmacy, Korle Bu Teaching Hospital

Dr. F. Ofei Department of Medicine, University of Ghana Medical School

Dr. (Mrs.) E.Ofori- University Health Services, University of Ghana
Adjei

Programme Managers:

Dr. N. A. Addo National AIDS/STI Control Programme

Dr.K.O. Antwi-Agyei Expanded Programme on Immunization (EPI), (GHS)

Dr. (Mrs.) C. Bart-Plange National Malaria Control Programme, (GHS)

Dr. F. Bonsu National Tuberculosis Programme, (GHS)

Dr. J. Gyapong Onchocerciasis Control Programme

Dr. (Mrs.) M. Hagan Eyecare Programme, (GHS)

Dr. (Mrs.) H. Odoi-Agyarko Reproductive and Childhealth Unit, (GHS)

Dr. R.K. Osei Ag. Head, Disease Control Unit, Ghana Health Service (GHS)

Dr. (Mrs.) I. Sagoe-Moses Intergrated Management of Childhood Illnesses (IMCI)

Royal Netherlands Embassy:

Dr. Jan van der Horst Health, Women and Development Advisor

World Health Organisation (WHO)

Dr. M. George The Country Representative, WHO, Ghana

Ms. E. Andrews National Professional Officer, Essential Drugs and Medicines Policy

Management Sciences for Health (MSH)

Dr. G. Tetteh MSH/RPM Plus

GNDP Steering Committee

Hon. M. Dani-Baah	Hon. Deputy Minister for Health
Mad. S. Abdul-Salam	Director, Admin., Ministry of Health (MOH)
Dr. K. Ahmed	Chief Medical Officer, (MOH)
Prof. A. B. Akosa	Director-General, Ghana Health Service
Mr. S. Boateng	Director, Procurement & Supplies, MOH
Dr. S. Akor	Director, Policy, Planning, Monitoring & Evaluation, MOH
Mr. P. Nomo	Financial Controller, MOH
Prof. D. Ofori-Adjei	Director, Noguchi Memorial Institute for Medical Research (NMIMR)
Mr. F. Yellu	Chief Pharmacist, Ghana Health Service
Mr. H.K. Abutiati	Chairperson, Pharmacy Council
Prof. G. Lutterodt	Chairperson, Food & Drugs Board
Dr. I. Agyepong	Regional Director of Health Services, GAR
Mrs. M. Gyansa-Lutterodt	Ag. Programme Manager, GNDP

GNDP Team:

Prof. D. Ofori-Adjei	Technical Consultant
Mrs. M. Gyansa-Lutterodt	Ag. Programme Manager
Ms. N. Frempong	Programme Officer
Dr. (Mrs.) Priscillia Nortey	STG Review Co-ordinator
Mrs. S. Ntow	Programme Accountant
Ms. M. Amoah	Office Manager

PREFACE

Essential Medicines are those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness.

This edition of the Essential Medicines List (EML) 2004 for Ghana has been derived from its companion Standard Treatment Guidelines 2004 to ensure harmony in treatment, procurement and re-imburements.

I hope that all health providers would embrace this document as it continues to be an important tool in the management of medicines in the country while the Ministry strives to increase access to essential medicines that satisfy the priority health care needs of all Ghanaians.



Dr. Kwaku Afriyie
Hon. Minister of Health
December 2004

INTRODUCTION

The medicines listed in this document are derived from the revised Standard Treatment Guidelines (2004) of the Ministry of Health. The criteria used to guide the selection of medicines were dependent on those used for the selection of medicines for the World Health Organisation Model List of Essential Medicines

The revision of the Standard Treatment Guidelines was based on published evidence or expert opinion. The final document was then field-tested among all categories of health professionals. As a consequence, medicines mentioned for the treatment of health problems in the Standard Treatment Guidelines have been included in this edition of the Essential Medicines List. In addition, comments on the 2000 Essential Medicines List collected from health professionals were considered on the basis of the WHO criteria by an expert panel. The criteria are:

- drug selection should be based on the results of efficacy and safety evaluations obtained in controlled clinical trials and epidemiological studies, and on the performance in general use in a variety of medical settings;
- when several drugs are available for the same indication, only the drug and the pharmaceutical form that provides the more convenient benefit/risk ratio should be selected;
- when two or more drugs are therapeutically equivalent, the selection should fall on:
 - the drug that has been more thoroughly investigated,
 - the drug with the most favourable pharmacokinetic properties,
 - the drug with the lowest cost, calculated on the basis of the whole course of treatment,
 - the drug with which health workers are already familiar,
 - the drug for which economically convenient manufacturing is available in the country,
 - the drug which shows better stability at the available storage conditions;

A fixed dose combination should be accepted only if clinical documentation justifies the concomitant use of more than one drug, and the combination provides a proven advantage over single compounds administered separately in therapeutic effect, safety, patients' compliance or cost.

Furthermore, guidelines are proposed to confine the circulation of essential drugs to specific and appropriate settings and levels of health care delivery. For this, drugs have been grouped into the following categories:

- Level A - Community
- Level B1 - Health Centre without Doctor
- Level B2 - Health Centre with Doctor
- Level C - District Hospital
- Level D - Regional/Teaching Hospital

Level SD - Specialist Drugs

Level PD - Programme Drugs

Specialist Drugs are restricted for use by qualified specialists who may request for them. Programme Drugs are those drugs used in public health programmes of the Ministry of Health and as such used within the guidelines of the specific programmes.

In previous editions, the British Approved Name (BAN) was adopted for all medicines in the Essential Medicines List (EML). This current issue uses only the Recommended International Non-Proprietary Name (rINN) in line with WHO recommendations and practice.

It is the hope of the Ministry that health professionals will support this document by providing comments and suggestions towards to inform the next review

Comments and suggestions should be sent to:

The Programme Manager
Ghana National Drugs Programme
Ministry of Health
P.O. Box MB-582
Accra, Ghana
Tel +233 (0) 21 661 670/1
Fax: +233 (0) 21 664309
E-mail: gndp@ighmail.com

ESSENTIAL MEDICINES LIST

1 ANAESTHETICS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
1.1 GENERAL ANAESTHETICS		
	Halothane, Inhalation	C
	Isoflurane, Inhalation	SD
	Ketamine Injection, 10 mg/ml in 20 ml	C
	Ketamine Injection, 100 mg/ml in 10 ml	C
	Nitrous Oxide, Inhalation	C
	Oxygen (Medicinal Gas) Inhalation	C
	Propofol Injection, 10 mg/ml	D
	Thiopental Sodium Injection, 500 mg	C
	Thiopental Sodium Injection, 1 g	C
1.2 LOCAL ANAESTHETICS		
	Bupivacaine + Glucose Injection, (5 mg+80 mg) in 4ml	D
	Bupivacaine Injection, 2.5 mg/ml	D
	Bupivacaine Injection, 5 mg/ml	D
	Lidocaine Gel, 2%	B1
	Lidocaine Gel, 4%	B1

Lidocaine Injection, 0.5%	B1
Lidocaine Injection, 1%	D
Lidocaine Injection, 2%	B
Lidocaine Spray, 10%	B1
Lidocaine+Adrenaline Injection, 10 mg/ml+5 microgram/ml	B2
Lidocaine+Adrenaline Injection, 20 mg/ml+5 microgram/ml	B2
Prilocaine Injection, 10 mg/ml	D

2 PRE-OPERATIVE MEDICATIONS AND SEDATION FOR SHORT-TERM PROCEDURES

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Atropine Injection, 0.6 mg/ml	B2
	Diazepam Injection, 5 mg/ml	B1
	Doxapram Injection, 20 mg/ml in 5 ml	D
	Ephedrine HCl Injection, 3 mg/ml	D
	Glycopyrronium Injection, 200 microgram/ml	D
	Lorazepam Injection, 4 mg/ml	D
	Midazolam Injection, 2 mg/ml	D
	Midazolam Injection, 5 mg/ml	D

3 ANALGESICS, ANTIPYRETICS, NSAIDS AND DRUGS USED IN GOUT

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
3.1 NON-OPIOID NON-STEROIDAL ANALGESICS		
	Acetyl Salicylic Acid Tablet, 300 mg	A
	Allopurinol Tablet, 100 mg	C
	Allopurinol Tablet, 300 mg	C
	Diclofenac Injection, 25 mg/ml	B2
	Diclofenac Suppository, 50 mg	C
	Diclofenac Suppository, 100 mg	C
	Diclofenac Tablet, 25 mg	B2
	Diclofenac Tablet, 50 mg	B2
	Ibuprofen Suspension, 100mg/5ml	B1
	Ibuprofen Tablet, 200 mg	B1
	Ibuprofen Tablet, 400 mg	B2
	Paracetamol Suppository, 125 mg	B1
	Paracetamol Suppository, 250 mg	B1
	Paracetamol Syrup, 120 mg/5 ml	A
	Paracetamol Tablet, 500 mg	A

3.2 OPIOD ANALGESICS

Fentanyl Citrate Injection, 50 microgram/ml	D
Morphine Injection, 10 mg/ml	C
Morphine Injection, 10 mg/ml (Preservative Free)	SD
Morphine Sulphate Tablet, 30 mg (Slow release)	D
Pethidine Injection, 50 mg/ml in 2 ml	B2

4 ANTI-ALLERGIC DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Adrenaline Injection, (1:1000) 1 mg/ml	B1
	Cetirizine Tablet, 10 mg	C
	Chlorphenamine Syrup, 2 mg/5 ml	B1
	Chlorphenamine Tablet, 4 mg	B1
	Dexamethasone Tablet, 500 microgram	C
	Diphenhydramine Tablet, 25 mg	B1
	Hydrocortisone Sodium Succinate Injection, 100 mg	B1
	Prednisolone Tablet, 5 mg	C
	Promethazine Elixir, 5 mg/5 ml	B1
	Promethazine Injection, 25 mg/ml in 2 ml	B1
	Promethazine Tablet, 25 mg	B1

5 ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
5.1 NON-SPECIFIC ANTIDOTES		
	Activated Charcoal Powder, 50 g	C
	Ipecacuanha Emetic Mixture, BP	C
5.2 SPECIFIC ANTIDOTES		
	Acetylcysteine Injection, 200 mg/ml	C
	Atropine Injection, 0.6 mg/ml	B2
	Benzatropine Injection, 1 mg/ml	C
	Naloxone Injection, 400 microgram/ml	B2
	Polystyrene Sulphonate Resins Powder, 300g	C
	Protamine Sulphate Injection, 10mg/ml	D

6 ANTICONVULSANTS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Carbamazepine Tablet, 100 mg	D
	Carbamazepine Tablet, 200 mg	D
	Diazepam Injection, 5 mg/ml in 2 ml	B1

Diazepam Rectal Tubes, 2 mg/ml	B1
Ethosuximide Syrup, 250 mg/5 ml	D
Ethosuximide Capsule, 250 mg	D
Magnesium Sulphate Injection, 20%	C
Magnesium Sulphate Injection, 25%	C
Magnesium Sulphate Injection, 50%	C
Phenobarbitone Elixir, 15 mg/5 ml	B2
Phenobarbital Injection, 200 mg/ml	B2
Phenobarbital Tablet, 30 mg	B2
Phenobarbital Tablet, 60 mg	B2
Phenytoin Sodium Capsule, 100 mg	B2
Phenytoin Injection, 50 mg/ml	D
Phenytoin Sodium Tablet, 100 mg	B2
Primidone Tablet, 250 mg	C
Sodium Valproate Tablet, 200 mg	D
Sodium Valproate Syrup, 200 mg/5ml	D

7 ANTI-INFECTIVE DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
-------------------	--	---------------

7.1 ANTIHELMINTHIC DRUGS

7.1.1 Intestinal Anthelmintic Drugs

Albendazole Syrup, 100 mg/5ml	B1
Albendazole Tablet, 200 mg	B1
Mebendazole Tablet, 100 mg	B1
Mebendazole Tablet, 500 mg	B1
Niclosamide Tablet, 500 mg	C
Tiabendazole Suspension, 50 mg/ml	C
Tiabendazole Tablet, 500 mg	C

7.1.2 Antifilarial Drugs

Diethylcarbamazine Tablet, 50 mg	B1
Ivermectin Tablet, 6 mg	B1

7.1.3 Antischistosomal Drugs

Praziquantel Tablet, 600 mg	B2
-----------------------------	----

7.2 ANTIBACTERIAL DRUGS

7.2.1 Penicillins

Amoxicillin Capsule, 250 mg	B1
Amoxicillin Capsule, 500 mg	B1
Amoxicillin Suspension, 125 mg/5 ml	B2
Amoxicillin + Clavulanic acid Suspension, 250mg + 62 mg	C
Amoxicillin + Clavulanic acid Suspension, 400mg + 57 mg	C

Amoxicillin + Clavulanic acid Injection, 500 mg + 100 mg	C
Amoxicillin + Clavulanic acid Tablet, 500 mg + 125 mg	C
Ampicillin Injection, 500 mg	C
Benzathine Benzylpenicillin Injection, 1.2 MU	B1
Benzathine Benzylpenicillin Injection, 2.4 MU	B1
Benzyl Penicillin Injection, 1 MU	B2
Benzyl Penicillin Injection, 5 MU	B2
Cloxacillin Injection, 250 mg	B2
Cloxacillin Injection, 500 mg	B2
Flucloxacillin Capsule, 250 mg	B2
Flucloxacillin Injection, 250 mg	C
Flucloxacillin Injection, 500 mg	C
Flucloxacillin Suspension, 125 mg/5 ml	B2
Phenoxymethyl Penicillin Tablet, 250 mg	B1
Procaine benzylpenicillin Injection, 4 MU	B1
Tetracycline Capsule, 250mg	B1

7.2.2 Other Antibacterial Drugs

Azithromycin Capsule, 250 mg	C
Azithromycin Oral suspension, 200 mg/5 ml	C
Cefotaxime Injection, 1 g	D
Cefotaxime Injection, 500 mg	D
Ceftriazone Injection, 1g vial	D
Ceftriazone Injection, 250 mg vial	PD
Cefuroxime Injection, 750 mg vial	D
Cefuroxime Injection, 1.5 mg vial	D
Cefuroxime Tablet, 250 mg	D
Chloramphenicol Capsule, 250 mg	B2
Chloramphenicol Injection, 1g	C
Chloramphenicol Suspension, 250 mg/5 ml	B2
Ciprofloxacin Infusion, 2 mg/ml in 100ml	D
Ciprofloxacin Tablet, 250 mg	PD
Ciprofloxacin Tablet, 500 mg	PD
Clarithromycin Tablet, 250 mg	D
Clarithromycin Tablet, 500 mg	D
Clarithromycin Paediatric Suspension, 125 mg/5 ml	D
Clindamycin Capsule, 150 mg	D
Clindamycin Injection, 150 mg/ml in 2ml	D
Cotrimoxazole Suspension, (200 mg+40 mg)/5 ml	B1
Cotrimoxazole Tablet, (400 mg+80 mg)	B1
Doxycycline Capsule, 100 mg	PD
Erythromycin Injection, 500 mg	D
Erythromycin Injection, 1 g	D
Erythromycin Syrup, 125 mg/5 ml	C

Erythromycin Tablet, 250 mg	C
Gentamicin Injection, 40 mg/ml in 2 ml	C
Neomycin Tablet, 500 mg	C
Nitrofurantoin Tablet, 100 mg	B2

7.2.3 Antileprosy Drugs

Antileprosy Pack (Clofazimine Tablet, 100 mg, Dapsone Tablet, 50 mg, Rifampicin Capsule, 300 mg)	PD
Dapsone Tablet, 100 mg	D

7.2.4 Antituberculous Drugs

Ethambutol Tablet, 400 mg	PD
Isoniazid Tablet, 100 mg	PD
Isoniazid+Thiacetazone Tablet, (300 mg+150 mg)	PD
Pyrazinamide Suspension, 125 mg/5 ml	PD
Pyrazinamide Tablet, 500 mg	PD
Rifampicin Tablet, 150mg	PD
Rifampicin + Isoniazid Suspension, 75 mg+50 mg/5 ml	PD
Rifampicin+Isoniazid Tablet, 150 mg+100 mg	PD
Streptomycin Injection, 1 g	PD
Thiacetazone Tablet, 150 mg	PD

7.3 ANTIFUNGAL DRUGS FOR SYSTEMIC USE

Fluconazole Capsule, 50 mg	SD
Fluconazole Capsule, 200 mg	SD
Griseofulvin Tablet, 125 mg	C
Griseofulvin Tablet, 500 mg	C
Ketoconazole Tablet, 200 mg	D
Nystatin Suspension, 100,000 IU/ml	B2
Nystatin Pastilles, 100,000 IU	C
Nystatin Tablet, 500,000 IU	C
Terbinafine HCl, Tablet, 250 mg	SD

7.4 ANTIPROTOZOAL DRUGS

7.4.1 Anti-Amoebic Drugs

Metronidazole Injection, 5 mg/ml in 100 ml	D
Metronidazole Suppository, 500 mg	C
Metronidazole Suspension, 100 mg/5ml (as benzoate)	B1
Metronidazole Suspension, 200 mg/5 ml (as benzoate)	B2
Metronidazole Tablet, 200 mg	B1
Metronidazole Tablet, 400 mg	B1

7.4.2 Antileishmaniasis Drugs

Pentamidine isetionate Injection, 300 mg vial	C
---	---

7.4.3 Antimalarial Drugs

Amodiaquine Syrup, 50 mg/ml	PD
Amodiaquine Tablet, 75 mg	PD
Amodiaquine Tablet, 150 mg	PD
Amodiaquine Tablet, 200 mg	PD
Artesunate Tablets, 25 mg	PD
Artesunate Tablets, 50 mg	PD
Artesunate Tablets, 100 mg	PD
Artesunate Tablets, 200 mg	PD
Quinine Injection, 300 mg/ml in 2 mls	PD
Quinine Tablet, 300 mg	PD
Sulfadoxine+Pyrimethamine Tablet, 525 mg	PD

7.5 ANTIVIRAL

Aciclovir Tablet, 200mg	D
Aciclovir Injection, 25mg/ml	D
Aciclovir Suspension, 200mg/5ml	D

8 ANTIMIGRAINE DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Acetyl Salicylic Acid Tablet, 300 mg	B1
	Ergotamine Tablet, 2 mg	C
	Paracetamol Tablet, 500 mg	B1
	Propranolol Tablet, 40mg	B2

9 ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
--------------------------	---	----------------------

9.1 CYTOTOXIC DRUGS

Fluorouracil Injection, 50 mg/5ml	D
Mercaptopurine Tablet, 50 mg	D
Dactinomycin Injection, 500 microgram	D
Azathioprine Tablet, 50 mg	D
Busulfan Tablet, 2 mg	D
Busulfan Tablet, 500 microgram	D
Cisplatin Injection, 50mg	D
Chlorambucil Tablet, 2 mg	D
Chlorambucil Tablet, 5 mg	D
Cyclophosphamide Injection, 500 mg	D
Cyclophosphamide Tablet, 25 mg	D
Cyclophosphamide Tablet, 50 mg	D
Cytosine Arabinoside Injection, 100 mg	D

Doxorubicin Injection, 10 mg	D
Doxorubicin Injection, 50 mg	D
Folinic Acid Injection, 15 mg	D
Folinic Acid Tablet, 15 mg	D
Hydroxycarbamide Tablet, 500mg	D
Melphalan Tablet, 2 mg	D
Melphalan Tablet, 5 mg	D
Methotrexate Injection, 2.5 mg	D
Methotrexate Injection, 25 mg	D
Methotrexate Tablet, 2.5 mg	D
Methotrexate Tablet, 10 mg	D
Procarbazine Tablet, 50 mg	D
Tioguanine Tablet, 40 mg	D
Vincristine Injection, 1 mg/ml	D
Vincristine Injection, 5 mg/ml	D

9.2 HORMONES AND ANTIHORMONES

Anastrozole Tablet, 1mg	D
Prednisolone Tablet, 5 mg	D
Diethylstilboestrol Tablet, 1 mg	D
Diethylstilboestrol Tablet, 5 mg	D
Tamoxifen Tablet, 10 mg	D
Tamoxifen Tablet, 20 mg	D

10 ANTIPARKINSONISM DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Trihexyphenidyl Tablet, 2 mg	C
	Trihexyphenidyl Tablet, 5 mg	C
	Benzatropine Injection, 1 mg/ml	C
	Benzatropine Tablet, 2 mg	C
	Biperiden Injection, 5 mg/ml	C
	Biperiden Tablet, 2 mg	C

11 DRUGS AFFECTING THE BLOOD

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
11.1 ANTIANAEMIA DRUGS		
	Iron + Folic Acid Tablet, 60 mg + 250 microgram	A
	Ferric Ammonium Citrate (FAC)	A
	Ferrous Fumarate Tablet, (100 mg Iron)	B1
	Ferrous Gluconate Tablet, (35 mg Iron)	B1
	Ferrous Sulphate (BPC) Syrup, 60 mg/5 ml	B1

Ferrous Sulphate Tablet, 60 mg (Elemental Iron)	B1
Folic Acid Tablet, 5 mg	B1
Hydroxocobalamin Injection, 1 mg/ml	C
Iron Dextran Injection, 50 mg/ml	C

11.2 ANTICOAGULANTS AND ANTAGONISTS

Acetyl Salicylic Acid Tablet, 75 mg	C
Heparin [Low molecular weight] Injection, 4000 units/ml	D
Heparin Injection, 1000 units/ml	D
Heparin Injection, 5000 units/ml	D
Heparin Injection, 5000 units/0.2 ml	D
Protamine Sulphate Injection, 10mg/ml	D
Phytomenadione Injection, 10 mg/ml	C
Phytomenadione Injection, 1 mg/ml	B2
Warfarin Tablet, 1 mg	D
Warfarin Tablet, 3 mg	D
Warfarin Tablet, 5 mg (scored)	D

12 BLOOD PRODUCTS AND BLOOD SUBSTITUTES

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Gelatin Infusion (succinylated gelatin)	C

13 CARDIOVASCULAR DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
-------------------	--	---------------

13.1 ANTI-ANGINAL DRUGS

Glyceryl Trinitrate Sublingual Tablet, 500 microgram	C
Isosorbide Dinitrate Sublingual Tablet, 5 mg	C
Isosorbide Dinitrate Tablet, 10 mg	C
Nifedipine Tablet, 10 mg (slow release)	C
Nifedipine Tablet, 20 mg (slow release)	C
Nifedipine Tablet, 30mg (GITS)	C
Propranolol Tablet, 10mg	C
Propranolol Tablet, 40 mg	C
Propranolol Tablet, 80 mg	C

13.2 ANTIDYSRHYTHMIC DRUGS

Amiodarone Tablet, 200mg	SD
Disopyramide Capsule, 100mg	D
Disopyramide Phosphate Injection, 10mg/ml	D
Lidocaine Injection, 20 mg/ml in 5 mls	D

Propranolol Tablet, 10mg	C
Propranolol Tablet, 40 mg	C
Propranolol Tablet, 80 mg	C

13.3 ANTIHYPERTENSIVE DRUGS

Atenolol Tablet, 100 mg	C
Atenolol Tablet, 50 mg	C
Bendroflumethiazide Tablet, 2.5 mg	B1
Bendroflumethiazide Tablet, 5 mg	B1
Hydralazine Injection, 20 mg	C
Hydralazine Tablet, 25 mg	C
Labetalol Injection, 5 mg/ml	D
Labetalol Tablet, 100 mg	D
Labetalol Tablet, 200 mg	D
Lisinopril Tablet, 2.5 mg	D
Lisinopril Tablet, 5 mg	D
Lisinopril Tablet, 10 mg	D
Losartan Tablet, 25 mg	D
Losartan Tablet, 50 mg	D
Losartan Tablet, 100 mg	D
Methyldopa Tablet, 250 mg	B2
Nifedipine Capsule, 10 mg	D
Nifedipine Capsule, 5 mg	D
Nifedipine Tablet, 10 mg (Slow release)	C
Nifedipine Tablet, 20 mg (Slow release)	C
Nifedipine Tablet, 30 mg (GITS)	C
Prazosin Tablet, 500 microgram	D
Propranolol Injection, 1 mg/ml	D
Propranolol Tablet, 10 mg	B2
Propranolol Tablet, 40 mg	B2
Propranolol Tablet, 80 mg	B2
Reserpine Injection, 1 mg/ml	B2
Reserpine Tablet, 250 microgram	B1

13.4 CARDIAC GLYCOSIDES

Digoxin Elixir, 50 microgram/ml	C
Digoxin Injection, 250 microgram/ml	C
Digoxin Tablet, 125 microgram	C
Digoxin Tablet, 250 microgram	C

13.5 LIPID-REGULATING DRUGS

Fluvastatin Capsules, 20mg	D
----------------------------	---

13.6 DRUGS USED IN SHOCK

Dopamine Injection, 40 mg/ml in 5 ml	D
Hydrocortisone Injection, 100 mg	C

14 DERMATOLOGICAL PREPARATIONS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
--------------------------	---	----------------------

14.1 ANTIFUNGAL DRUGS

Benzoic Acid + Salicylic Acid Ointment, 6%+3%	B1
Clotrimazole + Hydrocortisone Cream, 2% + 1%	D
Clotrimazole Cream, 2%	B2
Clotrimazole Pessary, 100 mg	PD
Gentian Violet Paint, 1%	A
Selenium Sulphide Shampoo, 2.5%	C

14.2 ANTI-INFECTIVE DRUGS

Aciclovir Cream, 5%	C
Cetrimide Solution	B1
Chlorhexidine Cream, 1%	B1
Chlorhexidine Solution, 2.5%	B1
Silver Sulfadiazine Cream, 1%	C

14.3 ANTI-INFLAMMATORY AND ANTIPRURITIC DRUGS

Calamine Lotion, 15%	B1
Calamine Cream, 15%	B1
Clobetasol propionate Cream, 0.05%	B1
Hydrocortisone Cream, 1%	C

14.4 ASTRINGENT AGENTS

Salicylic Acid Ointment, 2%	B1
-----------------------------	----

14.5 SCABICIDES AND PEDICULOCIDES

Benzyl Benzoate Lotion, 25%	B1
Lindane Lotion, 1%	B1

14.6 EMOLLIENTS AND VEHICLES

Aqueous Cream BP	B1
------------------	----

14.7 OTHERS

Benzoyl Peroxide Solution, 10%	C
Benzoyl Peroxide Solution, 5%	C
Clindamycin Solution, 1%	C
Mercurochrome Solution	B1

15 DIAGNOSTIC AGENTS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
15.1 OPHTHALMIC DRUGS		
	Fluorescein Solution, 2%	C
	Fluorescein Strips	C
	Methylcellulose Eye Drops, 1%	D
	Methylcellulose Eye Drops, 2%	D
	Rose Bengal Minims, 1%	D
	Tropicamide Eye Drops, 1%	C
15.2 BED-SIDE DIAGNOSTIC SUPPORT		
	Diagnostic Strips - Glucose	B1
	Diagnostic Strips - Multipurpose	B2
	Diagnostic Strips - Protein	B2
	Diagnostic Tablets - Glucose	B1
	Diagnostic Tablets - Ketones	B1
15.3 OTHERS		
	Edrophonium Injection, 10 mg/ml	D

16 DISINFECTANTS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Chlorhexidine Solution, 4% in detergent base	C
	Chlorhexidine Cream, 1%	C
	Chlorhexidine Solution, 2.5%	B1
	Iodine + Potassium Iodide Solution, 2% + 2.4%	A
	Povidone Iodine (aq.) Solution, 10%	B1

17 DIURETICS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Bendroflumethiazide Tablet, 2.5 mg	B1
	Bendroflumethiazide Tablet, 5 mg	B1
	Furosemide Injection, 10 mg/ml in 2 ml	B2
	Furosemide Tablet, 40 mg	B2
	Mannitol Injection, 10% 500 ml	C
	Mannitol Injection, 20% 500 ml	D
	Metolazone Tablet, 5 mg	D
	Spironolactone Tablet, 25 mg	C
	Spironolactone Tablet, 50 mg	C

18 GASTROINTESTINAL DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
18.1 ANTACIDS AND OTHER ANTIULCER DRUGS		
	Magnesium Trisilicate Mixture	B1
	Magnesium Trisilicate Tablet, 500 mg	A
	Omeprazole Capsule, 20 mg	D
	Ranitidine Injection, 25 mg/ml in 2ml	C
	Ranitidine Tablet, 150 mg	C
18.2 ANTI-EMETICS		
	Metoclopramide Injection, 5 mg/ml in 2 mls	D
	Metoclopramide Tablet, 10 mg	C
	Ondansetron Injection, 2 mg/ml	SD
	Ondansetron Tablet, 4 mg	SD
	Promethazine Hydrochloride Elixir, 5 mg/5 ml	B2
	Promethazine Hydrochloride Injection, 25 mg/ml	B2
	Promethazine Theoclate Tablet, 25 mg	B2
18.3 ANTIHAEMORRHOIDAL DRUGS		
	Ethanolamine Oleate Solution, 5%	D
	Phenol 5% in Almond Oil Injection	D
	Soothing Agent + Local Anaesthetic Ointment	B2
	Soothing Agent + Local Anaesthetic Suppository	B2
	Soothing Agent + Local Anaesthetic + Steroid Ointment	C
	Soothing Agent + Local Anaesthetic + Steroid Suppository	C
18.4 ANTI-INFLAMMATORY DRUGS		
	Sulfasalazine Tablet, 500 mg	D
18.5 ANTISPASMODIC DRUGS		
	Hyoscine Butylbromide Tablet, 10 mg	B2
	Hyoscine Butylbromide Injection, 20 mg/ml	B2
	Mebeverine Tablet, 135 mg	D
18.6 CATHARTIC DRUGS		
	Bisacodyl Tablet, 5 mg	B2
	Lactulose Liquid 3.1- - 3.7 g/5 ml	C
	Magnesium Sulphate salt	C
	Paraffin Liquid	B1
	Senna Tablet, 7.5 mg or Granules	B1
18.7 DRUGS USED IN DIARRHOEA		
18.7.1 Oral Replacement Solution		

Oral Rehydration Salts Powder A

18.7.2 Antidiarrhoeal (Symptomatic) Drugs

Codeine Tablet, 30mg C

19 HORMONES, OTHER ENDOCRINE DRUGS AND CONTRACEPTIVES

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
-------------------	--	---------------

19.1 ADRENAL HORMONES AND SYNTHETIC SUBSTITUTES

	Dexamethasone Injection, 4 mg/ml	C
	Fludrocortisone Tablet, 100 microgram	D
	Hydrocortisone Sodium Succinate Injection, 100 mg	B2
	Prednisolone Tablet, 5 mg	C

19.2 ANDROGENS

	Testosterone Enanthate Injection, 200 mg in 1 ml ampoule	D
--	--	---

19.3 CONTRACEPTIVES

	Medroxyprogesterone Acetate Injection, 150 mg/ml (Depot)	PD
--	--	----

19.4 ESTROGENS

	Conjugated Oestrogen Tablet, 625 microgram	D
	Conjugated Oestrogen + Norgesterol Tablet, 625 microgram + 150 microgram	C
	Conjugated Oestrogen Vaginal cream, 625 micrograms/g	D

19.5 INSULINS AND OTHER ANTIDIABETIC DRUGS

	Isophane Insulin Injection (HM), 100 units/ml in 10 ml	C
	Insulin pre-mixed (30/70) HM Injection, 100 units/ml in 10 ml	C
	Insulin Soluble HM, 100 units/ml in 10 ml	C
	Glibenclamide Tablet, 5 mg	C
	Gliclazide Tablet, 80 mg	C
	Tolbutamide Tablet, 500 mg	C
	Metformin Tablet, 500 mg	D
	Glucagon Injection, 1 mg	C

19.6 OVULATION INDUCERS

	Clomifene Tablet, 50 mg	D
--	-------------------------	---

19.7 PROGESTOGENS

	Medroxyprogesterone Acetate Tablet, 5 mg	D
--	--	---

Norethisterone Tablet, 5 mg D

19.8 THYROID HORMONES AND ANTITHYROID DRUGS

Carbimazole Tablet, 5 mg D

Carbimazole Tablet, 20 mg D

Levothyroxine sodium Tablet, 50 microgram D

Levothyroxine sodium Tablet, 100 microgram D

19.9 OTHER ENDOCRINOLOGICAL DRUGS

Bromocriptine Tablet, 2.5 mg D

20 IMMUNOLOGICALS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
-------------------	--	---------------

20.1 DIAGNOSTIC AGENTS

Tuberculin (PPD) Injection	C
----------------------------	---

20.2 SERA AND IMMUNOGLOBULINS

Anti D Rh Immune Globulin Injection	C
-------------------------------------	---

Antirabies immunoglobulins Injection, 1000 IU/5ml	B1
---	----

Anti-snake venom, Polyvalent Injection	B1
--	----

Tetanus Immunoglobulins Injection, 250 IU/ml	B1
--	----

20.3 VACCINES

20.3.1 For Universal Immunization

BCG Vaccine Injection	PD
-----------------------	----

"Five in One" Vaccine Injection (Diphtheria, Pertussis, Tetanus, Haemophilus influenzae b and Hepatitis B)	PD
--	----

Hepatitis B Vaccine Injection	PD
-------------------------------	----

Measles Vaccine Injection	PD
---------------------------	----

Poliomyelitis Vaccine Oral Solution	PD
-------------------------------------	----

Tetanus Vaccine Injection, 40 IU/5 ml	PD
---------------------------------------	----

Yellow Fever Vaccine Injection	PD
--------------------------------	----

20.3.2 For Specific Groups of Individuals

Meningococcal Vaccine Injection	B2
---------------------------------	----

Rabies Vaccine Injection	B2
--------------------------	----

Tetanus Toxoid Injection, 0.5 ml	B1
----------------------------------	----

Tetanus Vaccine Injection, 40 IU/5 ml	B1
---------------------------------------	----

Yellow Fever Vaccine Injection	B2
--------------------------------	----

21 MUSCLE RELAXANTS AND CHOLINESTERASE INHIBITORS*

* Level of Care may be altered in accordance with type of anaesthetic machine and

personnel available

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
	Atracurium Injection, 10 mg/ml in 2.5 ml	D
	Neostigmine Injection, 2.5 mg	D
	Neostigmine Injection, 0.5 mg	D
	Rocuronium Injection, 10 mg/ml	
	Suxamethonium Injection, 100 mg/2ml	C
	Vecuronium Bromide Injection, 10 mg/vial	D

22 OPHTHALMOLOGICAL PREPARATIONS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
22.1 ANTI-INFECTIVE AGENTS		
	Aciclovir Ointment, 3%	D
	Chloramphenicol Eye Drops, 1%	B1
	Chloramphenicol Eye Ointment, 1%	B1
	Econazole Eye Drops, 1%	C
	Erythromycin Ointment, 0.5%	B1
	Gentamicin Eye Drops, 0.3%	D
	Gentamicin Ointment, 0.3%	D
	Sulphacetamide Eye Drops, 10%	B1
	Sulphacetamide Ointment, 10%	B1
	Tetracycline Eye Drops, 0.5% 10 mls	B1
	Tetracycline Ointment, 1%	B1
22.2 ANTI-INFLAMMATORY AGENTS		
	Corticosteroid + Antibiotic Drops	D
	Corticosteroid + Antibiotic Ointment	D
	Dexamethasone Eye Drops, 1%	D
	Dexamethasone Eye Ointment, 1%	D
	Hydrocortisone Eye Drops, 1%	D
	Hydrocortisone Eye Ointment, 1%	D
	Lodoxamide Eye Drops, 0.1%	D
	Prednisolone Eye Drops, 0.5%	D
	Prednisolone Eye Drops, 1%	D
22.3 LOCAL ANAESTHETICS		
	Tetracaine Eye Drops, 0.5%	C
22.4 MIOTICS AND DRUGS USED IN GLAUCOMA		
	Acetazolamide Injection, 500 mg	D
	Acetazolamide Tablet, 250 mg	C

Adrenaline Eye Drops, 1%	D
Betaxolol HCl Eye Drops, 0.5%	D
Pilocarpine Eye Drops, 2%	D
Pilocarpine Eye Drops, 4%	D
Timolol Maleate Eye Drops, 0.5%	D

22.5 MYDRIATICS

Atropine Eye Drops, 1%	D
Cyclopentolate Eye Drops, 1%	D
Homatropine Eye Drops, 2%	C

22.6 OTHERS

Methyl Cellulose Eye Drops, 0.3%	C
----------------------------------	---

23 OXYTOCICS AND ANTI-OXYTOCICS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
-------------------	--	---------------

23.1 OXYTOCICS

Ergometrine Injection, 0.5 mg/ml	B1
Ergometrine Tablet, 0.5 mg	A
Misoprostol Vaginal Tablet,, 200 microgram	C
Oxytocin Injection, 5 units/ml	C

23.2 ANTI-OXYTOCICS

Salbutamol Sulphate Injection, 500 microgram/ml	C
Salbutamol Tablet, 4 mg	C

24 PERITONEAL DIALYSIS SOLUTIONS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
-------------------	--	---------------

Intraperitoneal Dialysis Solution, Hypertonic	D
Intraperitoneal Dialysis Solution, Hypotonic	D

25 PSYCHOTHERAPEUTIC DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
-------------------	--	---------------

Amitriptyline Tablet, 10 mg	D
Amitriptyline Tablet, 25 mg	D
Amitiptyline Tablet, 50 mg	D
Chlorpromazine Injection, 25 mg/ml in 2 mls	B2
Chlorpromazine Tablet, 100 mg	B2
Chlorpromazine Tablet, 25 mg	B2
Chlorpromazine Tablet, 50 mg	B2

Diazepam Injection, 5 mg/ml in 2 ml	B2
Diazepam Tablet, 10 mg	B2
Diazepam Tablet, 5 mg	B2
Fluoxetine Capsule, 20 mg	D
Fluphenazine Deconoate Injection, 25 mg/ml	D
Haloperidol Injection, 5 mg/ml	D
Haloperidol Tablet, 10 mg	D
Haloperidol Tablet, 5 mg	D
Imipramine Tablet, 25 mg	D
Lorazepam Tablet, 2.5 mg	D
Risperidone Liquid, 1 mg/ml	SD
Risperidone Tablet, 500 microgram	SD
Risperidone Tablet, 1mg	SD
Risperidone Tablet, 2mg	SD
Trifluoperazine Tablet, 1 mg	D
Trifluoperazine Tablet, 5 mg	D

26 DRUGS ACTING ON THE RESPIRATORY TRACT

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
-------------------	--	---------------

26.1 ANTI-ASTHMATIC DRUGS

Adrenaline Injection, 1 mg/1ml (1:1000)	B1
Aminophylline Injection, 250 mg/10 ml	B2
Beclometasone dipropionate Inhaler, 100 mcg/metered dose	B2
Beclometasone dipropionate Inhaler, 50 mcg/metered dose	B2
Hydrocortisone Sodium Succinate Injection, 100 mg	B2
Prednisolone Tablet, 5 mg	C
Salbutamol Inhaler, 100 microgram/metered dose, 200 doses	B2
Salbutamol Nebulizer, 2.5 mg Nebules	C
Salbutamol Nebulizer, 5 mg Nebules	C
Salbutamol Syrup, 2 mg/5 ml	B1
Salbutamol Tablet, 2 mg	B1
Salbutamol Tablet, 4 mg	B1
Theophylline Dry Syrup, 60 mg/5 ml	D
Theophylline Tablet, 200 mg (slow release)	C

26.2 ANTITUSSIVES

Dihydrocodeine Tablet, 30 mg	C
Simple Linctus (paediatric)	B1
Simple Linctus Syrup	B1

27 SOLUTIONS CORRECTING WATER AND ELECTROLYTE

ABNORMALITIES

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
--------------------------	---	----------------------

27.1 ORAL PREPARATIONS

	Oral Rehydration Salts Powder	A
	Potassium Chloride Tablet, 600 mg (enteric coated)	C

27.2 PARENTERAL SOLUTIONS

	Badoe's Solution Injection, 1000 ml	C
	Cholera Replacement Fluid Injection, (5:4:1)	B
	Darrow's Solution Injection, Half-Strength 250 ml	C
	Dextrose in Sodium Chloride Intravenous Infusion, 4.3% in 0.18% 250 ml	C
	Dextrose in Sodium Chloride Intravenous Infusion, 5% in 0.9% (500 ml)	C
	Dextrose [†] in Sodium Chloride Intravenous Infusion, 10% in 0.18% (250 ml)	C
	Dextrose Infusion, 10% (250 ml)	B2
	Dextrose Infusion, 10% (500 ml)	B2
	Dextrose Infusion, 20% (250 ml)	C
	Dextrose Infusion, 5% (250 ml)	B
	Dextrose Infusion, 5% (500 ml)	B
	Dextrose Infusion, 50% (50 ml)	B2
	Potassium Chloride Injection, 20 mEq/10 ml	C
	Ringer's Lactate Intravenous Infusion, 500 ml	B2
	Sodium Bicarbonate Injection, 8.4% in 10 ml	C
	Sodium Chloride + KCl Injection, 0.9% + 20 mMol (500 ml)	D
	Sodium Chloride in Dextrose Injection, 0.9% in 5% (500 ml)	B2
	Sodium Chloride Injection, 0.9% (250 ml)	B1
	Sodium Chloride Injection, 0.9% (500 ml)	B1
	Sodium Chloride Injection, 0.45% (250 ml)	C

27.3 MISCELLANEOUS

	Water for Injection	A
--	---------------------	---

[†]*Dextrose is used interchangeably with Glucose*

28 VITAMINS AND MINERALS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
--------------------------	---	----------------------

	Calciferol Tablet, 10,000 units	C
	Calcium Gluconate Injection, 100 mg/ml in 10 ml	C

Multivitamin Syrup	B1
Multivitamin Tablet	B1
Retinol Soft Capsule, 200,000 IU	B1
Retinol Soft Capsule, 100,000 IU	B1
Thiamine Injection, 100 mg	D
Thiamine Tablet, 25 mg	D

29 OTHER SPECIALIST DRUGS

THERAPEUTIC CLASS	NAME OF DRUG, DOSAGE FORM AND STRENGTH	LEVEL OF CARE
29.1 DRUGS FOR EAR, NOSE AND THROAT		
	Sodium Chloride Nasal Drops, 0.9%	B1
29.2 DRUGS FOR DENTISTRY		
	Chlorhexidine Mouthwash, 0.2%	B2
	Lidocaine + Adrenaline Cartridge, 20 mg/ml + [1:80,000/1:100,000]	B2
	Miconazole Oral gel, 25 mg/ml	B2
	Nystatin Ointment, 100,000 IU	B2
29.3 DRUGS FOR HIV/AIDS		
	Abacavir oral solution, 20 mg/ml	SD
	Abacavir Tablet, 300 mg	SD
	Didanosine Capsule, 200 mg	SD
	Didanosine Oral solution, 10 mg/ml	SD
	Didanosine Tablet, 25 mg,	SD
	Didanosine Tablet, 50 mg	SD
	Didanosine Tablet, 100 mg	SD
	Didanosine Tablet, 150 mg	SD
	Efavirenz Capsule, 50 mg	SD
	Efavirenz Capsule, 100 mg	SD
	Efavirenz Capsule, 200 mg	SD
	Efavirenz Syrup, 30 mg/ml	SD
	Efavirenz Tablet, 600 mg	SD
	Indinavir Tablet, 400 mg	SD
	Lamivudine Oral solution, 10 mg/ml	SD
	Lamivudine Tablet, 150 mg	SD
	Liponavir with Ritonavir Capsule, 133.3 mg + 33.3 mg	SD
	Liponavir with Ritonavir Oral solution, 80 mg + 20 mg/ml	SD
	Nelfinavir Tablet, 250 mg	SD
	Nevirapine Suspension, 10 mg/ml	SD
	Nevirapine Tablet, 200 mg	SD
	Ritonavir Capsule, 100 mg	SD
	Saquinavir Capsule, 200 mg	SD

Stavudine Capsule, 15 mg	SD
Stavudine Capsule, 20 mg	SD
Stavudine Capsule, 30 mg	SD
Stavudine Capsule, 40 mg	SD
Stavudine Oral Solution, 1 mg/ml	SD
Tenofovir Tablet, 300 mg	SD
Zidovudine Capsule, 100 mg	SD
Zidovudine Syrup, 10 mg/ml	SD
Zidovudine Tablet, 300 mg	SD
Zidovudine + Lamivudine Tablet, 300 mg +150 mg	SD

29.4 DRUGS FOR UROLOGY

Tamsulosin Capsule, 400 microgram	D
Terazosin Tablet, 2 mg	D
Terazosin Tablet, 5 mg	D
Finasteride Tablet, 5 mg	D

OTHER PUBLICATIONS

- National Drugs Policy (2004)
- Code of Ethics and Standards of Practice for Traditional Medicines Practitioners in Ghana (2004)
- Standards of Pharmaceutical Care for Health Institutions in Ghana (2003)
- Increasing Access to Medicines: An Assessment and Policy Options for Ghana (2003)
- An Assessment of the Pharmaceutical Sector in Ghana (2002)
- Logistics Management of Public Sector Health Commodities in Ghana: Standard Operating Procedures - Regional Medical Stores to Service Delivery Points (2002)
- Drugs and Therapeutics Committee (DTC) Training Manual (2002)
- Standard Treatment Guidelines (2000)
- Ghana Essential Drugs List (2000)
- Baseline Survey on the Pharmaceutical Sector in Ghana (1999)
- Procurement Procedure Manual (1999)
- Procurement Training Manual
- Rational Drug Use Training Manual

**Ghana National Drugs Programme (GNDP)
Ministry of Health**

P.O. Box MB-582, Accra, Ghana, West Africa
Tel: +233 (0) 21 661 670/+233 (0) 21661671
Fax: +233 ©21 664309
E-mail: gndp@ighmail.com
Website: www.moh-ghana.org

ISBN 9988-8283-2-2